Charlotte Figi, Charlotte's Web & the CBD Turn

Charlotte Figi was born on October 18, 2006, in Colorado Springs. She was a twin. By the time she was three months old, she was having seizures. The diagnosis was Dravet syndrome — a severe form of epilepsy caused by a genetic mutation affecting sodium ion channels in the brain. Dravet is rare, debilitating, and largely resistant to conventional treatment. By the time Charlotte was five, she was experiencing more than 300 grand mal seizures per week. She was confined to a wheelchair. She had stopped speaking. Every pharmaceutical intervention her parents and doctors attempted had failed.

The Stanley brothers

Joel, Jesse, Jon, Jordan, Jared, and Josh Stanley were six brothers operating a cannabis cultivation facility in Colorado. They had been crossbreeding cannabis strains and had produced a cultivar that was high in cannabidiol (CBD) and very low in tetrahydrocannabinol (THC). The strain had no recreational market — users reported no psychoactive effect. The brothers called it "Hippie's Disappointment."

The Figi family, desperate after years of failed treatments, approached the Stanley brothers. Charlotte began treatment with an oil extract derived from the high-CBD strain. The results were immediate and dramatic.

Charlotte's seizures dropped from more than 300 per week to two or three per month. She began walking again. She began speaking again. The transformation was not a cure — Dravet syndrome has no cure — but it was the most significant improvement her family and doctors had seen from any intervention.

The Stanley brothers renamed the strain Charlotte's Web.

Sanjay Gupta and the CNN documentary

On August 11, 2013, CNN aired "Weed," a documentary by chief medical correspondent Dr. Sanjay Gupta. Charlotte Figi's story was the centerpiece. Gupta, a neurosurgeon who had previously written against medical cannabis, reversed his position on camera. His public apology was direct: "I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing remarkable research. I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis."

The documentary reached an audience that reform advocates and clinical researchers had never been able to access. The image of a seven-year-old girl — not a counterculture figure, not a political activist, not someone who could be dismissed as seeking recreational access under a medical pretext — whose seizures had been brought under control by a cannabis extract that did not produce a high was transformative. It reframed the medical cannabis debate from an argument about marijuana to an argument about a suffering child.

Cannabis refugees

The documentary triggered a migration. More than 500 families with children suffering from severe epilepsy moved to Colorado in the months following the broadcast. They called themselves cannabis refugees — families who uprooted their lives and moved to a state where they could legally access a treatment that their home states prohibited. The phenomenon exposed the cruelty of the state-by-state patchwork: the same treatment that was legal in Colorado was a felony in many of the states these families fled.

Legislative and regulatory consequences

Charlotte's story catalyzed legislative action at both state and federal levels. States that had resisted medical cannabis began passing narrow "CBD-only" laws — legislation that authorized CBD extracts while continuing to prohibit cannabis in all other forms. These laws were often inadequate in practice but represented a political breakthrough: legislators who would never have voted for a medical cannabis bill could support a measure framed around pediatric epilepsy.

The trajectory from Charlotte's Web to Epidiolex traced the path the FDA requires: anecdotal evidence, clinical investigation, controlled trials, approval. The FDA's approval of Epidiolex in 2018 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome was the federal government's first official acknowledgment that a cannabis-derived compound had accepted medical use — directly contradicting the Schedule I classification that held, as a matter of federal law, that cannabis had none.

Charlotte's story also contributed to the political momentum behind the 2018 Farm Bill, which removed hemp (cannabis with less than 0.3% THC) from the Controlled Substances Act entirely. The demand for CBD products that Charlotte's Web had created was a significant commercial and political force behind the hemp legalization provisions.

Charlotte's death

Charlotte Figi died on April 7, 2020, at the age of thirteen. The cause was likely complications from COVID-19, though she had been hospitalized with seizure-related issues prior to contracting the virus. Governor Jared Polis proclaimed Charlotte Figi Day in her honor.

She had lived seven years longer than anyone expected when her seizures were at their worst. In those years, she changed American drug policy more profoundly than any other single patient in the history of cannabis reform — not through advocacy, not through litigation, but simply by getting better when nothing else had worked.